GLP-1 Receptor Agonists Show Promise for Longevity and Metabolic Health
New England Journal review explores the expanding therapeutic potential of GLP-1 drugs beyond diabetes treatment.
Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
294 articles
New England Journal review explores the expanding therapeutic potential of GLP-1 drugs beyond diabetes treatment.
Major study of 30,458 patients finds surgery achieves 28% weight loss vs 10% with GLP-1 drugs, while costing significantly less long-term.
New research highlights the critical need for culturally tailored digital health tools to improve diabetes management outcomes.
New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.
Multi-omic analysis reveals GLP-1 receptor agonists counter aging processes across multiple organ systems and biological pathways.
Deep dive into uncoupling protein 1 mechanisms, sympathetic nervous system control, and therapeutic strategies for metabolic health and longevity.
New research reveals how SEC16B protein regulates glucose homeostasis by controlling insulin secretion in pancreatic beta cells.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
Large NHANES study shows TyG-ABSI index better predicts cardiovascular disease and death in metabolic syndrome patients than standard measures.
New review exposes stark disparities in diabetes care across Asia-Pacific, from insulin access to advanced technologies like CGM and pumps.
Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.
Comprehensive review reveals hexokinase method as the most precise technique for glucose testing in clinical laboratories.